Results 41 to 50 of about 2,540 (169)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update

Metabolites, 2023
It has been consistently demonstrated that circulating lipids and particularly low-density lipoprotein cholesterol (LDL-C) play a significant role in the development of coronary artery disease (CAD).
Fabiana Lucà, Fabrizio Oliva, Carmelo Massimiliano Rao, Maurizio Giuseppe Abrignani, Antonio Francesco Amico, Stefania Angela Di Fusco, Giorgio Caretta, Irene Di Matteo, Concetta Di Nora, Anna Pilleri, Roberto Ceravolo, Roberta Rossini, Carmine Riccio, Massimo Grimaldi, Furio Colivicchi, Michele Massimo Gulizia   +15 more
doaj   +1 more source

Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases

Biomedicines, 2021
Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties.
Victoria A. Korneva, Tatjana Yurjevna Kuznetsova, Ulrich Julius   +2 more
doaj   +1 more source

Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Clopidogrel is an antiplatelet agent widely utilized in cardiology. It is a prodrug activated in the liver by the cytochrome P450 isoform CYP2C19. Variability in the CYPC2C19 gene influences the activation and efficacy of clopidogrel. This is covered in guidelines from the Clinical Pharmacogenetics Implementation Consortium, the Dutch ...
Cinzia Dello Russo, Luigi Venetucci, Abisope Akintola, Dimitri Gagliardi, Ronnie Ramlogan, Munir Pirmohamed   +5 more
wiley   +1 more source

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin

Frontiers in Pharmacology
BackgroundInclisiran is an siRNA-based cholesterol-lowering drug with N-acetylgalactosamine carbohydrate (GalNAc) and is used for the treatment of hypercholesterolemia or dyslipidemia.
Fei Li, Huan Ye, Lingbin Chen, Yuanchun Ma, Sunhui Chen   +4 more
doaj   +1 more source

2021 FDA TIDES (Peptides and Oligonucleotides) Harvest

Pharmaceuticals, 2022
From the medical, pharmaceutical, and social perspectives, 2021 has been a year dominated by the COVID-19 pandemic. However, despite this global health crisis, the pharmaceutical industry has continued its endeavors, and 2021 could be considered an ...
Danah Al Shaer, Othman Al Musaimi, Fernando Albericio, Beatriz G. de la Torre   +3 more
doaj   +1 more source

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia

Journal of Cellular and Molecular Medicine, Volume 30, Issue 10, May 2026.
ABSTRACT Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab and evolocumab, effectively reduce LDL‐C levels, improve cardiovascular outcomes, and are well tolerated in the treatment of heterozygous familial hypercholesterolemia (HeFH).
Agnieszka Woźniak‐Szczepocka, Agnieszka Pawlos, Paulina Gorzelak‐Pabiś, Marlena Broncel, Bożena Bukowska, Ewelina Woźniak   +5 more
wiley   +1 more source

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy

International Journal of Molecular Sciences, 2023
Hypercholesterolemia plays a crucial role in the development of atherosclerosis, but it remains an undertreated and underdiagnosed disease. Taking into consideration the high prevalence of lipid disorders, long duration of the asymptomatic course of the disease, life-threatening complications resulting from inaccurate therapy, and stringent treatment ...
Adrianna Dec, Aleksandra Niemiec, Eliza Wojciechowska, Mateusz Maligłówka, Łukasz Bułdak, Aleksandra Bołdys, Bogusław Okopień   +6 more
openaire   +2 more sources

A Long‐Term Human Liver Spheroid Model for Assessing Silencing and Durability of GalNAc‐Conjugated siRNAs

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Advances in RNA interference technology have established it as a powerful therapeutic tool with important future potential. The design and the chemical modifications of the siRNA nucleotide backbone have greatly enhanced stability, durability, and pharmacokinetics while minimizing tolerability risks.
Gijs‐Jan Scholten, Clara Grundmann, Åsa Nordling, Caroline Coskun, Volker Engelhardt, Lingheswar Sadhasivam, Tomaž Einfalt, Magnus Ingelman‐Sundberg, Sander van Riet   +8 more
wiley   +1 more source

Dynamics of lipid metabolism parameters following the change of targeted therapy for hypercholesterolemia after acute coronary syndrome

Терапевтический архив
Aim. To evaluate lipid metabolism dynamics by switch from inclisiran to alirocumab in the setting of lipid-lowering therapy (LLT) after acute coronary syndrome (ACS). Materials and methods.
Aleksei A. Nekrasov, Elena S. Timoshchenko, Svetlana G. Erofeeva, Elena S. Kuzyakina, Tatiana A. Nekrasova   +4 more
doaj   +1 more source